128 related articles for article (PubMed ID: 38642550)
1. Myosin inhibitor reverses hypertrophic cardiomyopathy in genotypically diverse pediatric iPSC-cardiomyocytes to mirror variant correction.
Kinnear C; Said A; Meng G; Zhao Y; Wang EY; Rafatian N; Parmar N; Wei W; Billia F; Simmons CA; Radisic M; Ellis J; Mital S
Cell Rep Med; 2024 May; 5(5):101520. PubMed ID: 38642550
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes.
Ramachandra CJA; Kp MMJ; Chua J; Hernandez-Resendiz S; Liehn EA; Knöll R; Gan LM; Michaëlsson E; Jonsson MKB; Ryden-Markinhuhta K; Bhat RV; Fritsche-Danielson R; Lin YH; Sadayappan S; Tang HC; Wong P; Shim W; Hausenloy DJ
Cardiovasc Res; 2022 Jan; 118(2):517-530. PubMed ID: 33705529
[TBL] [Abstract][Full Text] [Related]
3. Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients.
Wu H; Yang H; Rhee JW; Zhang JZ; Lam CK; Sallam K; Chang ACY; Ma N; Lee J; Zhang H; Blau HM; Bers DM; Wu JC
Eur Heart J; 2019 Dec; 40(45):3685-3695. PubMed ID: 31219556
[TBL] [Abstract][Full Text] [Related]
4. Enhanced myofilament calcium sensitivity aggravates abnormal calcium handling and diastolic dysfunction in patient-specific induced pluripotent stem cell-derived cardiomyocytes with MYH7 mutation.
Guo G; Wang L; Li X; Fu W; Cao J; Zhang J; Liu Y; Liu M; Wang M; Zhao G; Zhao X; Zhou Y; Niu S; Liu G; Zhang Y; Dong J; Tao H; Zhao X
Cell Calcium; 2024 Jan; 117():102822. PubMed ID: 38101154
[TBL] [Abstract][Full Text] [Related]
5. Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy.
Toepfer CN; Garfinkel AC; Venturini G; Wakimoto H; Repetti G; Alamo L; Sharma A; Agarwal R; Ewoldt JK; Cloonan P; Letendre J; Lun M; Olivotto I; Colan S; Ashley E; Jacoby D; Michels M; Redwood CS; Watkins HC; Day SM; Staples JF; Padrón R; Chopra A; Ho CY; Chen CS; Pereira AC; Seidman JG; Seidman CE
Circulation; 2020 Mar; 141(10):828-842. PubMed ID: 31983222
[TBL] [Abstract][Full Text] [Related]
6. Myocardial Deformation Analysis in
Höller V; Seebacher H; Zach D; Schwegel N; Ablasser K; Kolesnik E; Gollmer J; Waltl G; Rainer PP; Verheyen S; Zirlik A; Verheyen N
Genes (Basel); 2021 Sep; 12(10):. PubMed ID: 34680864
[TBL] [Abstract][Full Text] [Related]
7. Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells.
Han L; Li Y; Tchao J; Kaplan AD; Lin B; Li Y; Mich-Basso J; Lis A; Hassan N; London B; Bett GC; Tobita K; Rasmusson RL; Yang L
Cardiovasc Res; 2014 Nov; 104(2):258-69. PubMed ID: 25209314
[TBL] [Abstract][Full Text] [Related]
8. Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics.
Bhagwan JR; Mosqueira D; Chairez-Cantu K; Mannhardt I; Bodbin SE; Bakar M; Smith JGW; Denning C
J Mol Cell Cardiol; 2020 Aug; 145():43-53. PubMed ID: 32531470
[TBL] [Abstract][Full Text] [Related]
9. A Premature Termination Codon Mutation in MYBPC3 Causes Hypertrophic Cardiomyopathy via Chronic Activation of Nonsense-Mediated Decay.
Seeger T; Shrestha R; Lam CK; Chen C; McKeithan WL; Lau E; Wnorowski A; McMullen G; Greenhaw M; Lee J; Oikonomopoulos A; Lee S; Yang H; Mercola M; Wheeler M; Ashley EA; Yang F; Karakikes I; Wu JC
Circulation; 2019 Feb; 139(6):799-811. PubMed ID: 30586709
[TBL] [Abstract][Full Text] [Related]
10. Association of variants in MYH7, MYBPC3 and TNNT2 with sudden cardiac death-related risk factors in Brazilian patients with hypertrophic cardiomyopathy.
Mori AA; Castro LR; Bortolin RH; Bastos GM; Oliveira VF; Ferreira GM; Hirata TDC; Fajardo CM; Sampaio MF; Moreira DAR; Pachón-Mateos JC; Correia EB; Sousa AGMR; Brión M; Carracedo A; Hirata RDC; Hirata MH
Forensic Sci Int Genet; 2021 May; 52():102478. PubMed ID: 33588347
[TBL] [Abstract][Full Text] [Related]
11. Generation of iPSC line from MYH7 R403L mutation carrier with severe hypertrophic cardiomyopathy and isogenic CRISPR/Cas9 corrected control.
Fontaine V; Duboscq-Bidot L; Jouve C; Hamlin M; Curjol A; Briand V; Janiak P; Hulot JS; Pruniaux-Harnist MP; Charron P; Villard E
Stem Cell Res; 2021 Apr; 52():102245. PubMed ID: 33610018
[TBL] [Abstract][Full Text] [Related]
12. Incomplete-penetrant hypertrophic cardiomyopathy
Lee S; Vander Roest AS; Blair CA; Kao K; Bremner SB; Childers MC; Pathak D; Heinrich P; Lee D; Chirikian O; Mohran SE; Roberts B; Smith JE; Jahng JW; Paik DT; Wu JC; Gunawardane RN; Ruppel KM; Mack DL; Pruitt BL; Regnier M; Wu SM; Spudich JA; Bernstein D
Proc Natl Acad Sci U S A; 2024 May; 121(19):e2318413121. PubMed ID: 38683993
[TBL] [Abstract][Full Text] [Related]
13. Unexpectedly low mutation rates in beta-myosin heavy chain and cardiac myosin binding protein genes in Italian patients with hypertrophic cardiomyopathy.
Roncarati R; Latronico MV; Musumeci B; Aurino S; Torella A; Bang ML; Jotti GS; Puca AA; Volpe M; Nigro V; Autore C; Condorelli G
J Cell Physiol; 2011 Nov; 226(11):2894-900. PubMed ID: 21302287
[TBL] [Abstract][Full Text] [Related]
14. iPSC-Based Modeling of Variable Clinical Presentation in Hypertrophic Cardiomyopathy.
Escribá R; Larrañaga-Moreira JM; Richaud-Patin Y; Pourchet L; Lazis I; Jiménez-Delgado S; Morillas-García A; Ortiz-Genga M; Ochoa JP; Carreras D; Pérez GJ; de la Pompa JL; Brugada R; Monserrat L; Barriales-Villa R; Raya A
Circ Res; 2023 Jul; 133(2):108-119. PubMed ID: 37317833
[TBL] [Abstract][Full Text] [Related]
15. Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations.
Witjas-Paalberends ER; Güçlü A; Germans T; Knaapen P; Harms HJ; Vermeer AM; Christiaans I; Wilde AA; Dos Remedios C; Lammertsma AA; van Rossum AC; Stienen GJ; van Slegtenhorst M; Schinkel AF; Michels M; Ho CY; Poggesi C; van der Velden J
Cardiovasc Res; 2014 Jul; 103(2):248-57. PubMed ID: 24835277
[TBL] [Abstract][Full Text] [Related]
16. Spectrum of Mutations in Hypertrophic Cardiomyopathy Genes Among Tunisian Patients.
Jaafar N; Gómez J; Kammoun I; Zairi I; Amara WB; Kachboura S; Kraiem S; Hammami M; Iglesias S; Alonso B; Coto E
Genet Test Mol Biomarkers; 2016 Nov; 20(11):674-679. PubMed ID: 27574918
[TBL] [Abstract][Full Text] [Related]
17. Utility of genetics for risk stratification in pediatric hypertrophic cardiomyopathy.
Mathew J; Zahavich L; Lafreniere-Roula M; Wilson J; George K; Benson L; Bowdin S; Mital S
Clin Genet; 2018 Feb; 93(2):310-319. PubMed ID: 29053178
[TBL] [Abstract][Full Text] [Related]
18. Screening of MYH7, MYBPC3, and TNNT2 genes in Brazilian patients with hypertrophic cardiomyopathy.
Marsiglia JD; Credidio FL; de Oliveira TG; Reis RF; Antunes Mde O; de Araujo AQ; Pedrosa RP; Barbosa-Ferreira JM; Mady C; Krieger JE; Arteaga-Fernandez E; Pereira Ada C
Am Heart J; 2013 Oct; 166(4):775-82. PubMed ID: 24093860
[TBL] [Abstract][Full Text] [Related]
19. A Contraction Stress Model of Hypertrophic Cardiomyopathy due to Sarcomere Mutations.
Cohn R; Thakar K; Lowe A; Ladha FA; Pettinato AM; Romano R; Meredith E; Chen YS; Atamanuk K; Huey BD; Hinson JT
Stem Cell Reports; 2019 Jan; 12(1):71-83. PubMed ID: 30554920
[TBL] [Abstract][Full Text] [Related]
20. MYBPC3-c.772G>A mutation results in haploinsufficiency and altered myosin cycling kinetics in a patient induced stem cell derived cardiomyocyte model of hypertrophic cardiomyopathy.
Steczina S; Mohran S; Bailey LRJ; McMillen TS; Kooiker KB; Wood NB; Davis J; Previs MJ; Olivotto I; Pioner JM; Geeves MA; Poggesi C; Regnier M
J Mol Cell Cardiol; 2024 Jun; 191():27-39. PubMed ID: 38648963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]